The Long-Term Effect of Specific Type II 5alpha-Reductase Inhibition with Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

    May 2002 in “ PubMed ”
    Alvin M. Matsumoto, Lisa Tenover, Michael R. McClung … Joanne Waldstreicher
    Studysummary In this study, long-term use of finasteride did not negatively impact bone mineral density in men with benign prostatic hyperplasia over a 4-year period.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pubmed.ncbi.nlm.nih.gov →
    Discuss this study in the Community →

    Research cited in this study 5

    1. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1998
    2. Bone Density Is Normal in Male Rats Treated with Finasteride Endocrinology · 1995
    3. Prolonged Treatment with Finasteride (a 5α-Reductase Inhibitor) Does Not Affect Bone Density and Metabolism Clinical Endocrinology · 1992
    4. The Effect of Finasteride in Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1992
    5. Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers The Journal of Clinical Endocrinology and Metabolism · 1990

    Related research 1

    1. The Long-Term Effect of Specific Type II 5alpha-Reductase Inhibition with Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial PubMed · 2002